Tilray Brands, Inc. (NASDAQ:TLRY) has announced plans to restructure its Canadian cannabis operations by transferring cultivation and pre-roll production from its Foss facility in Fenwick, Ontario, to existing sites in Quebec and Ontario, as part of an initiative expected to deliver approximately $10 million in annualised cost savings.
The company will move cultivation activities to its Masson facility in Quebec, while pre-roll manufacturing will be consolidated at its Cayuga facility in Ontario.
Tilray expects the restructuring to improve operational efficiency, increase production capacity at Masson and support its international medical cannabis business.
Alongside the announcement, the company raised the lower end of its fiscal 2027 adjusted EBITDA guidance to $70 million, compared with its previous forecast of $68 million.
The consolidation is expected to be completed in phases, with operations at the Foss facility scheduled to end by January 31, 2027.
Tilray’s restructuring plan involves transferring production activities from its Foss facility in Fenwick, Ontario, to other locations within its existing Canadian operating network.
Cannabis cultivation will be relocated to Masson, Quebec, while pre-roll production will move to Cayuga, Ontario.
The company said the changes are intended to streamline its manufacturing and cultivation operations while making greater use of its established facilities.
By consolidating production, Tilray aims to reduce operating costs and improve efficiency across its Canadian cannabis business.
The restructuring will be implemented gradually to allow existing cultivation and harvesting activities at Foss to be completed before the facility closes.
Tilray expects all operations at Foss to conclude by January 31, 2027.
The company also confirmed that employees affected by the closure have been offered positions at other Tilray facilities.
Tilray expects the consolidation programme to produce approximately $10 million in annualised cost savings by the end of fiscal 2028.
The anticipated savings are linked to the transfer of cultivation and manufacturing activities into existing facilities.
The company expects the restructuring to reduce duplication across its operations and support a more efficient production network.
Tilray indicated that the full annualised savings run rate is expected to begin in fiscal 2028.
The projected savings represent a recurring annual benefit once the restructuring has been fully implemented, rather than an immediate reduction in costs.
The announcement did not specify the total restructuring expenses associated with closing Foss or transferring production to the other facilities.
Actual savings will depend on the successful completion of the transition and the performance of the consolidated operations.
A central component of the restructuring is the planned expansion of cultivation activities at Tilray’s Masson facility in Quebec.
The company expects annual cultivation capacity at Masson to increase from approximately 32.5 metric tonnes to 50 metric tonnes.
This represents an increase of 17.5 metric tonnes, or approximately 54%, in annual production capacity.
The additional capacity will support the transfer of cultivation activities from Foss while expanding Masson’s role within Tilray’s Canadian operating network.
Concentrating cultivation at Masson is intended to improve the utilisation of existing infrastructure and support the company’s broader production strategy.
However, the projected increase relates to cultivation capacity and does not necessarily indicate that actual production volumes will immediately reach 50 metric tonnes annually.
Tilray also expects its Masson facility to re-establish European Union Good Manufacturing Practice (EU-GMP) certification during calendar 2027.
The certification is an important regulatory requirement for supplying certain medical cannabis markets internationally.
Regaining EU-GMP status would expand Masson’s ability to participate in international medical cannabis supply chains.
The company expects the certification to support its efforts to increase access to overseas markets as it expands cultivation capacity at the facility.
The development forms part of Tilray’s broader strategy to strengthen its international medical cannabis operations.
However, the certification process has not yet been completed, and the announcement did not provide a specific approval date.
Tilray will consolidate its Canadian pre-roll production at its Cayuga facility in Ontario.
The decision follows continued growth in the pre-roll category, which has become an important part of the company’s Canadian adult-use cannabis business.
According to Tilray, pre-roll products account for approximately one-third of its Canadian adult-use sales.
The category recorded 28% growth during fiscal 2026.
The company expects the transfer of pre-roll manufacturing to Cayuga to support greater operational efficiency and provide a more centralised production structure.
The consolidation will also allow Tilray to focus manufacturing activities at a facility already included in its Canadian operating network.
The announcement did not disclose the planned production capacity for pre-rolls at Cayuga following the transfer.
Tilray plans to complete the closure of its Foss facility by January 31, 2027.
The transition will take place in phases to ensure that current cultivation and harvesting cycles can be completed before operations cease.
This approach is intended to support an orderly transfer of production activities to Masson and Cayuga.
The company said employees affected by the closure have been offered positions at other Tilray facilities.
However, Tilray did not disclose the number of employees affected or provide details about how many are expected to accept alternative roles.
The Foss closure forms part of the wider restructuring programme designed to consolidate Canadian cannabis production and reduce costs.
Alongside the operational restructuring, Tilray increased the lower end of its fiscal 2027 adjusted EBITDA forecast.
The company now expects adjusted earnings before interest, taxes, depreciation and amortisation of $70 million to $75 million.
This compares with its previous guidance range of $68 million to $75 million.
The revised forecast raises the lower end of the range by $2 million while leaving the upper end unchanged.
The midpoint of the new guidance is $72.5 million, compared with $71.5 million previously.
The increase indicates a modest improvement in management’s expectations for adjusted operating profitability during fiscal 2027.
However, the company expects the full $10 million annualised savings benefit from the restructuring to begin in fiscal 2028.
The revised EBITDA outlook therefore precedes the anticipated full financial contribution from the consolidation programme.
Tilray also provided an update on its international cannabis business.
Blair MacNeil, President of Tilray Canada, said the company expects to ship more than eight metric tonnes of cannabis to international markets during the current fiscal year.
The forecast highlights the importance of overseas demand within Tilray’s broader cannabis strategy.
The planned expansion of cultivation capacity at Masson and the expected restoration of EU-GMP certification could support the company’s international operations.
International medical cannabis markets are an important consideration in Tilray’s production planning, particularly where regulatory certifications are required.
However, the company did not provide a breakdown of expected shipments by country or disclose the anticipated revenue associated with the forecast volume.
Tilray’s Canadian cannabis operations currently encompass approximately 4.2 million square feet of cultivation capacity.
The company’s facilities are located across Leamington, Cayuga, Quebec and British Columbia.
The planned restructuring will concentrate selected activities within this existing network rather than establishing new production locations.
Masson will take on additional cultivation responsibilities, while Cayuga will become the consolidated location for pre-roll manufacturing.
The company expects this approach to support greater efficiency while maintaining its ability to serve domestic and international cannabis markets.
The announcement did not specify whether the restructuring will change Tilray’s total Canadian cultivation footprint once the Foss facility has closed.
Tilray’s latest restructuring initiative is intended to improve the efficiency of its Canadian cannabis operations while supporting future growth in international medical cannabis markets.
The transfer of cultivation activities to Masson is expected to increase that facility’s annual capacity to 50 metric tonnes, while the consolidation of pre-roll production at Cayuga follows 28% category growth in fiscal 2026.
The company expects approximately $10 million in annualised savings from the restructuring, with the full run rate anticipated in fiscal 2028.
At the same time, Tilray has raised its fiscal 2027 adjusted EBITDA guidance to $70 million–$75 million.
Investors will be monitoring the closure of Foss, the expansion of Masson’s cultivation capacity, progress towards EU-GMP certification and the company’s ability to achieve its projected cost savings.
The expected shipment of more than eight metric tonnes of cannabis internationally during the current fiscal year also provides a measure of Tilray’s ambitions beyond the Canadian domestic market.
Successful implementation of the consolidation programme will be important to achieving the company’s operational efficiency targets and supporting its longer-term profitability objectives.
Tilray stock price
| 4 hours | |
| 5 hours | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-22 | |
| Oct-21 | |
| Oct-15 | |
| Oct-13 | |
| Oct-12 | |
| Oct-08 | |
| Oct-08 | |
| Oct-08 | |
| Oct-08 | |
| Oct-08 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite